 The FDA has signed off Immunic Incs NASDAQ: IMUX investigational new drug application for the Phase 3 ENSURE program of lead asset IMU-838 in patients with relapsing-remitting multiple sclerosis. In addition, the FDA also gave a green signal to the companys separate IND application for the supportive Phase 2 CALLIPER trial of IMU-838 in patients with progressive multiple sclerosis PMS. 